mTOR Inhibition Is Most Beneficial After Liver Transplantation for Hepatocellular Carcinoma in Patients With Active Tumors

Schnitzbauer, Andreas A., Filmann, Natalie, Adam, René, Bachellier, Philippe, Bechstein, Wolf O., Becker, Thomas, Bhoori, Sherrie, Bilbao, Itxarone, Brockmann, Jens, Burra, Patrizia, Chazoullières, Olivier, Cillo, Umberto, Colledan, Michele, Duvoux, Christoph, Ganten, Tom M., Gugenheim, Jean, Heise, Michael, van Hoek, Bart, Jamieson, Neville, de Jong, Koert P., Klein, Christian G., Klempnauer, Jürgen, Kneteman, Norman, Lerut, Jan, Mäkisalo, Heikki, Mazzaferro, Vincenzo, Mirza, Darius F., Nadalin, Silvio, Neuhaus, Peter, Pageaux, George-Philippe, Pinna, Antonio D., Pirenne, Jaques, Pratschke, Johann, Powel, James, Rentsch, Markus, Rizell, Magnus, Rossi, Giorgio, Rostaing, Lionel, Roy, André, Scholz, Tim, Settmacher, Utz, Soliman, Thomas, Strasser, Simone, Söderdahl, Gunnar, Troisi, Roberto I., Turrión, Victor Sánchez, Schlitt, Hans J. and Geissler, Edward K. (2020) mTOR Inhibition Is Most Beneficial After Liver Transplantation for Hepatocellular Carcinoma in Patients With Active Tumors. Annals of Surgery, Publis. ISSN 0003-4932.

Preview

Text 00000658-900000000-94220.pdf Download (734kB) | Preview

Item Type:	Article
Subjects:	QZ Pathology. Oncology
Divisions:	Planned IP Care > Oncology and Clinical Haematology
Related URLs:	https://pubmed.ncbi.nlm.nih.gov/32889867...
Depositing User:	Mr Philip O'Reilly
Date Deposited:	16 Sep 2020 09:43
Last Modified:	16 Sep 2020 09:43
URI:	http://www.repository.uhblibrary.co.uk/id/eprint/3426

Actions (login required)

View Item